Home » Stocks » EYEG

EyeGate Pharmaceuticals, Inc. (EYEG)

Stock Price: $3.93 USD -0.07 (-1.75%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 27.89M
Revenue (ttm) 12,059
Net Income (ttm) -8.09M
Shares Out 4.58M
EPS (ttm) -1.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $3.93
Previous Close $4.00
Change ($) -0.07
Change (%) -1.75%
Day's Open 3.97
Day's Range 3.90 - 4.09
Day's Volume 15,887
52-Week Range 3.20 - 8.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and ...

1 month ago - GlobeNewsWire

WALTHAM, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treati...

1 month ago - GlobeNewsWire

- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development -

3 months ago - GlobeNewsWire

WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treatin...

4 months ago - GlobeNewsWire

EyeGate Pharma shares doubled on Monday morning following the news of its acquisition of Austria's Panoptes Pharma. Zacks earlier boosted its target on EYEG stock to $15 a share.

4 months ago - InvestorPlace

Expands Pipeline Beyond Ophthalmology with PP-001 , a Clinical Stage, Best-in-Class DHODH Inhibitor

4 months ago - GlobeNewsWire

Investors Should Be Excited For EyeGate's Ocular Bandage

1 year ago - Seeking Alpha

Eyegate: Speculative Buy For Their Better-Than-SOC Treatment In Corneal Wound Repair

1 year ago - Seeking Alpha

Shares of EyeGate Pharmaceuticals Inc. rallied 95% in premarket trading on the news that the company's experimental eye-drop bandage performed better than the standard of care, which is a bandage contac...

1 year ago - Market Watch

Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE).

1 year ago - Benzinga

About EYEG

EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveit... [Read more...]

Industry
Biotechnology
CEO
Stephen From
Employees
14
Stock Exchange
NASDAQ
Ticker Symbol
EYEG
Full Company Profile

Financial Performance

In 2020, EYEG's revenue was $12,059, a decrease of -99.55% compared to the previous year's $2.69 million. Losses were -$8.09 million, 14.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for EYEG stock is "Buy." The 12-month stock price forecast is 12.13, which is an increase of 208.65% from the latest price.

Price Target
$12.13
(208.65% upside)
Analyst Consensus: Buy